ATP2C2

Across TCGA pan-cancer cohorts, ATP2C2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ATP2C2 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher ATP2C2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP2C2 expression acts as an unfavorable survival marker.

ACC, HNSC, and LUSC are the cancer types where ATP2C2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.010	0.667	<.001	45	view →
HNSC	OS	Median	II,III,IV	0.275	0.676	.005	30	view →
LUSC	OS	Median	III,IV	0.112	0.664	.003	12	view →
GBM	DFS	Median	All	0.060	0.257	.005	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ATP2C2–ACC (DFS)

Open the ACC breakdown →